On October 1, 2025, Elutia Inc. announced the closing of its sale of the BioEnvelope business to Boston Scientific Corporation. The transaction, valued at $88 million, includes the EluPro™ and CanGaroo® bioenvelope products. The deal was announced as a GlobeNewswire release from Elutia’s headquarters in Gaithersburg, Md.
Boston Scientific will integrate the bioenvelope technology into its breast reconstruction portfolio, expanding its biologics offerings. The acquisition aligns with the company’s strategy to strengthen its presence in the breast reconstruction market, which has a U.S. addressable market of approximately $1.5 billion. The addition is expected to generate incremental revenue and enhance product differentiation for the company.
The closing of the sale demonstrates Boston Scientific’s continued focus on strategic tuck‑in acquisitions to broaden its product pipeline. By adding Elutia’s bioenvelope platform, the company gains a complementary technology that can be paired with its existing breast reconstruction devices. The transaction is expected to support long‑term growth and provide new revenue streams for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.